9 / 26
Page 48
conferenceseries
.com
Volume 5, Issue 7 (Suppl)
J Infect Dis Ther, an open access journal
ISSN: 2332-0877
Infection Prevention 2017
December 14-15, 2017
December 14-15, 2017 | Rome, Italy
13
th
World Congress on
INFECTION PREVENTION AND CONTROL
Opportunities for development of new anti-infective medicines
Tomislav Kostyanev
University of Antwerp, Belgium
A
ntibiotic resistance (ABR) has now been recognized as a global public health threat, causing at least 700,000 death cases
every year. Therefore, it is essential that new and rapid solutions are found to effectively overcome the consequences of
ABR. Many pharmaceutical companies have found difficulties to invest in antibiotic drug discovery and development in the last
two decades, mainly because of low economic return of investment. The innovative medicines initiative joint undertaking (IMI
JU) has addressed this issue by investing more than 660 million euro in seven projects clustered in the New Drugs for Bad Bugs
programme. These projects encompass all aspects of drug development from basic science and drug discovery, through clinical
development to new business models and responsible use of antibiotics. The main objectives of the COMBACTE consortia
are to deliver clinical trials in collaboration with pharmaceutical companies and to build clinical and laboratory networks to
optimise scientific evaluation of new antimicrobials within Europe. The COMBACTE consortium now consists of 55 academic
and 8 industrial partners and spreads in 42 countries, including more than 800 hospitals. The main objective of LAB-Net,
one of the four pillars of COMBACTE, is to establish a European-wide network of laboratories that plays a key role in clinical
trials on anti-infectives. By being part of LAB-Net, laboratories can benefit from training programmes and activities to build
laboratory capacity and infrastructure. One of the ultimate goal of COMBACTE is to evolve into a self-sustainable clinical trial
infrastructure which will support trials of anti-infectives after the formal close-out of the IMI-funded programme. The vision
of such a network would be to efficiently generate rigorous evidence for new or improved diagnosis, prevention and treatment
of infections and to better respond to infectious disease threats. This would be facilitated by a European multidisciplinary
clinical network and innovative research approaches.
tomislav.kostyanev@uantwerpen.beJ Infect Dis Ther 2017, 5:7(Suppl)
DOI: 10.4172/2332-0877-C1-036